Humacyte, Inc. (HUMA)
| Market Cap | 597.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -152.87M |
| Shares Out | 128.67M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75,069,349 |
| Open | 5.780 |
| Previous Close | 3.460 |
| Day's Range | 4.450 - 6.770 |
| 52-Week Range | 2.480 - 9.970 |
| Beta | 1.38 |
| Analysts | Strong Buy |
| Price Target | 13.14 (+183.19%) |
| Earnings Date | Nov 8, 2024 |
About HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for HUMA stock is "Strong Buy." The 12-month stock price forecast is $13.14, which is an increase of 183.19% from the latest price.
News
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options NEW YORK...
Humacyte stock may fail to sustain today's gains: find out more
Shares of Humacyte Inc (NASDAQ: HUMA) nearly doubled on Friday after receiving full approval for its flagship SYMVESS product from the US Food and Drug Administration (FDA). Regulatory approval for th...
The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Humacyte Inc.
LOS ANGELES, CA / ACCESSWIRE / December 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or...
Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles - Hagens Berman
SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2024 / Humacyte insiders recently offloaded a significant portion of company stock, raising eyebrows amidst a brewing legal storm. According to recent SEC...
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?
On Thursday, the FDA granted full approval to Humacyte, Inc.'s HUMA Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when urgent reva...
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –
Humacyte, Inc. Is Being Sued For Violating Securities Laws And Affected Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or...
Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles – Hagens Berman
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte insiders recently offloaded a significant portion of company stock, raising eyebrows amidst a brewing legal storm. According to recent SEC fil...
Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA
NEW YORK , Dec. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class per...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit – HUMA
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).
The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Case Against Humacyte Inc
LOS ANGELES, CA / ACCESSWIRE / December 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options If you su...
Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman
SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, a biotechnology company focused on regenerative medicine, is now facing an investor class action alleging that the company misled investors a...
The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Humacyte Inc
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or...
Humacyte, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA
NEW YORK , Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class per...
Humacyte, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or...
The Schall Law Firm Urges Stockholder Participation In A Securities Fraud Case Against Humacyte Inc
LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or...
Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations - Hagens Berman
HUMA Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / December 13, 2024 / Humacyte, a biotechnology company focused on regenerative medicine, is now facing an inve...
Humacyte, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Assist The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or...
The Schall Law Firm Encourages Shareholder Participation In A Fraud Case Against Humacyte Inc
LOS ANGELES, CA / ACCESSWIRE / December 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or...
Humacyte, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Help The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or ...
The Schall Law Firm Encourages Stockholder Participation In A Securities Fraud Case Against Humacyte Inc
LOS ANGELES, CA / ACCESSWIRE / December 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or ...
Humacyte, Inc. Is Being Sued For Violating Securities Regulations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or ...
The Schall Law Firm Invites Stockholder Contributions To A Securities Fraud Case Against Humacyte Inc
LOS ANGELES, CA / ACCESSWIRE / December 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or ...
Humacyte Inc. Is Being Sued For Violating Securities Regulations And Investors With Losses Are Urged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or ...